Titlebook: Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy; A Handbook for Diagn Maria E. Suarez-Almazor,Leonard H. Calabrese Book 20

誰(shuí)在削木頭

978-3-030-56823-8Springer Nature Switzerland AG 2021

OVERT

否認(rèn)

ALIAS

Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principlesumor immune response. Glucocorticoids are the first-line agent, but they should be used with caution and limited in both dose and duration if possible. Early referral to rheumatology is the key to addressing the issues in these complex patients. More human trials using DMARDs and biologic treatments are necessary.

小官

http://image.papertrans.cn/r/image/830082.jpg

撫慰

https://doi.org/10.1007/978-3-030-56824-5Cancer immunotherapy and rheumatic diseases; Cancer immunotherapy and arthritis; Cancer immunotherapy

新星

Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Polymyalgia Rheumatica clinical variant with potentially different pathogenesis, clinical course, and treatment responsiveness. While these patients can present classically, it seems they may also present with atypical clinical features and require higher than expected doses of glucocorticoids or even glucocorticoid-sparing agents.

JAMB

FUSE

Cancer Immunotherapy in Patients with Preexisting Inflammatory Arthritisexisting rheumatoid arthritis exposed to ICI for melanoma and followed longitudinally is presented in detail to highlight the clinical course and management challenges faced when caring for these patients.

V切開(kāi)